Research We Fund
With hundreds of projects currently underway, we fund scientists through our academic grant programs and biotech partners through our strategic venture philanthropy initiative. Use the filters below to find an LLS-funded project.
For a better viewing experience, please use a larger device.
Jennifer Amengual, MD
Columbia University Medical Center
New York, New YorkDefining ctDNA monitoring and immune modulation in a novel, risk stratified clinical trial for PTLD
Posttransplant lymphoproliferative disorders (PTLD) are a group of lymphomas that arise during immunosuppression following organ transplantation and are a significant source of morbidity and mortality. PTLD remains challenging to treat due to disease heterogeneity, patient comorbidities, the risk of infectious complications, and organ rejection. The goals of this proposal are to (1) study the therapeutic efficacy and safety of dose modified R-EPOCH in High-Risk PTLD patients; (2) determine the utility of ctDNA defined molecular response as a novel risk-stratification biomarker in PTLD; (3) understand the impact of immune-suppression on T cell function, T cell receptor diversity, and the detection of oncoviruses. The overall goal is to reduce morbidity and identify novel biomarkers for personalized precision treatment decisions to improve survival in this devastating disease.
Program: Academic Clinical Trials Program (ACT)Project Term: Start Date: February 1, 2025 End Date: January 31, 2028
Fahmin Basher, MD, PhD
Duke University Medical Center
Durham, North CarolinaThe Role of the DNA Sensor AIM2 in B Cell Fate and Function After HCT
Altered B cell homeostasis plays a key role in the development of chronic graft-vs-host-disease (cGVHD) after hematopoietic stem cell transplantation (HCT). We hypothesize that the DNA sensor AIM2 plays a critical role in the fate of BCR-activated B cells after HCT. We will utilize novel mouse models to investigate AIM2-BCR modulation with clear translational implications in autoreactivity perpetuating cGVHD as well as functional humoral deficiency and vaccine hyporesponsiveness after HCT.
Program: Career Development ProgramProject Term: Start Date: July 1, 2024 End Date: June 30, 2027
Pooja Khandelwal, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OhioA randomized clinical trial of oral vitamin A to reduce chronic graft versus host disease in BMT
Vitamin A is safe, well tolerated and positively affects gut immune health. Graft versus host disease (GVHD) is a life-threatening complication of bone marrow transplant (BMT) which happens due to inflammatory changes in the gut. We harnessed the anti-inflammatory properties of vitamin A by giving it to children before bone marrow transplant (BMT) and showed reduction in acute gut and moderate/severe chronic GVHD. We will validate our findings in this currently proposed study of an independent group of adult BMT patients. We will give vitamin A or placebo before BMT to adult BMT patients and observe for reduction of chronic GVHD in vitamin A recipients compared to placebo. This study will be a step forward in adoption of vitamin A as a universal strategy to prevent GVHD which is affordable ($1.25 for entire treatment), non-toxic, and doesn’t suppress the immune system.
Program: Academic Clinical Trials Program (ACT)Project Term: Start Date: October 1, 2024 End Date: September 30, 2027
Nicoletta Cieri, MD, PhD
Dana-Farber Cancer Institute
Boston, MassachusettsTCR-like CARs targeting GvL mHAgs for the treatment of post-transplant AML relapse
AML recurrence is a devastating event after allo-HCT. I hypothesize that it could be counteracted through targeting of leukemia-restricted mHAgs via TCR-like CARs. I will identify scFVs recognizing mHAg:HLA complexes using a cell-free nanobody screening platform, and test the anti-leukemia activity and safety of CAR-Ts bearing such scFVs in vitro and in vivo. Through this approach, I will build a library of CAR constructs able to provide population-scale coverage for at-risk allo-HCT patients.
Program: Career Development ProgramProject Term: Start Date: July 1, 2024 End Date: June 30, 2026
Armin Rashidi, MD PhD
Fred Hutchinson Cancer Center
Seattle, WashingtonFecal microbiota transplantation to prevent acute GVHD after allogeneic stem cell transplantation
In up to half of patients with hematologic malignancies undergoing allogeneic stem cell transplantation, the trajectory of a smooth recovery toward cure is disrupted by acute graft-versus-host disease (aGVHD). Inspired by the role of intestinal microbial communities in aGVHD pathogenesis, we recently completed the largest fecal microbiota transplantation (FMT) trial to date in transplant recipients. We established the safety of standardized third-party FMT and characterized FMT effects on the microbiota, leading to the proposed randomized, placebo-controlled phase 2 trial of FMT to prevent aGVHD.
Program: Academic Clinical Trials Program (ACT)Project Term: Start Date: July 1, 2023 End Date: October 31, 2026
Pietro Genovese, PhD
Boston Children's Hospital
Boston, MassachusettsTowards clinical testing of epitope editing to enable novel adoptive immunotherapies
Innovations in gene engineering have made it possible to reprogram immune cells to attack specific targets on cancer cells, allowing the first adoptive cellular immunotherapies, known as CAR T cells, to be approved by the FDA for the treatment B lymphoblastic leukemia. A similar approach is currently under development for AML, but in contrast to B-ALL, there is no leukemia-specific target which would be amenable to targeting by immune cells without incurring severe adverse effects. Here, we aim to modify normal bone marrow stem cells used for allogeneic transplantation to make them resistant to CAR-T cells, thus enabling targeting proteins essential for tumor survival without the risk of severe toxicity on the healthy tissue counterpart.
Program: Translational Research ProgramProject Term: Start Date: July 1, 2023 End Date: June 30, 2026
Adi Nagler, PhD
Dana-Farber Cancer Institute
Boston, MassachusettsThe microbiome-induced immune response role in bronchiolitis obliterans syndrome following allogeneic hematopoietic cell transplantation
The microbiome is increasingly recognized as contributing to chronic graft-versus-host disease (cGVHD). I hypothesize that microbial antigens drive the devastating complication of bronchiolitis obliterans syndrome (BOS). To determine if such antigen targets are at the heart of BOS pathology, I will integrate spatial transcriptomic approaches, immunopeptidome analysis, and direct antigen specificity testing of TCRs from biospecimens collected from preclinical models and patient biospecimens.
Program: Career Development ProgramProject Term: Start Date: July 1, 2023 End Date: June 30, 2026
Robert Soiffer, MD
Dana-Farber Cancer Institute
Boston, MassachusettsUnderstanding and Overcoming Mechanisms of Immune Evasion after Allogeneic Transplant
Outcomes for patients with acute myelogenous leukemia who relapse after transplantation are dismal. This SCOR brings together an international group of collaborators with deep expertise in genomics, epigenetics, antigen presentation, and immune-regulation. They will focus on mechanisms of immune evasion by leukemia cells, identifying effective T cell responses to those evasive processes, and providing critical insights into the optimal approaches to model new and promising targets for immunotherapy with a goal of eliminating leukemia recurrence.
Program: Specialized Center of Research Program
Project Term: Start Date: October 1, 2022 End Date: September 30, 2027
Kirk Schultz, MD
University of British Columbia
VancouverA Polyomic Approach to Chronic Graft-versus-Host Disease (cGvHD) Biomarkers in Adults
Our team is the first to develop a polyomic pediatric cGvHD biomarker test for assessing the risk of developing cGvHD. A cooperative adult phase III clinical trial, CTTC1901, between Canada and Australia, focused on decreasing cGvHD (N=350 patients), offers an ideal opportunity to validate adult cGvHD biomarkers. This proposal will utilize the pediatric polyomic approach to validate a cGvHD risk assignment and diagnostic algorithm in adult hematopoietic stem cell transplant (HSCT).
Program: Translational Research ProgramProject Term: Start Date: July 1, 2022 End Date: June 30, 2025
Ravi Bhatia, MD
The University of Alabama at Birmingham
Birmingham, AlabamaPrediction and prevention of therapy-related myeloid neoplasms following autologous transplantation
The proposed studies will identify alterations in hematopoietic regulation that predict for risk for therapy-related myeloid neoplasm (TMN) and improve understanding of disease evolution to guide strategies to prevent TMN in patients receiving autologous hematopoietic cell transplantation (aHCT) for lymphoma. They will investigate alterations in hematopoietic function in peripheral blood stem cell used for aHCT, and serial evolution of hematopoietic defects leading to development of TMN.
Program: Translational Research ProgramProject Term: Start Date: July 1, 2022 End Date: June 30, 2025
Michael Keller, MD
Children's Research Institute
Washington, District of ColumbiaT-cell immunotherapy for prevention of COVID-19 following bone marrow transplantation
SARS-Cov-2 infections may be prolonged in cancer patients and may enable intrahost development of virulent viral variants. Adoptive immunotherapy with virus-specific T-cells has been an effective treatment for refractory viral infections in immunocompromised patients following HSCT. We propose to study the functionality of coronavirus-specific T-cells (CSTs) from healthy donors, and utilize CSTs as preventative therapy for patients undergoing bone marrow transplant in a phase I study.
Program: Translational Research ProgramProject Term: Start Date: July 1, 2021 End Date: June 30, 2024
Rizwan Romee, MD
Dana-Farber Cancer Institute
Boston, MassachusettsCytokine induced memory-like NK cell immunotherapy to target post transplant relapse
Coming soon.
Program: Career Development ProgramProject Term: Start Date: July 1, 2021 End Date: June 30, 2026